Suppr超能文献

相似文献

3
Significance of TIM-3 Expression in Resected Esophageal Squamous Cell Carcinoma.
Ann Thorac Surg. 2020 May;109(5):1551-1557. doi: 10.1016/j.athoracsur.2019.12.017. Epub 2020 Jan 24.
5
Prognostic Value of Lymphocyte Activation Gene-3 (LAG-3) Expression in Esophageal Squamous Cell Carcinoma.
J Cancer. 2018 Oct 20;9(22):4287-4293. doi: 10.7150/jca.26949. eCollection 2018.
6
CD103 tumor-infiltrating lymphocytes predict favorable prognosis in patients with esophageal squamous cell carcinoma.
J Cancer. 2019 Aug 28;10(21):5234-5243. doi: 10.7150/jca.30354. eCollection 2019.
9
Characterization of TIM-3 expression and its prognostic value in patients with surgically resected lung adenocarcinoma.
Lung Cancer. 2018 Jul;121:18-24. doi: 10.1016/j.lungcan.2018.04.009. Epub 2018 Apr 19.

引用本文的文献

1
LAG3 as a marker of immune activation in esophageal squamous carcinoma treated with concurrent chemoradiotherapy.
Cancer Immunol Immunother. 2025 May 24;74(7):215. doi: 10.1007/s00262-025-04076-2.
2
Current Advances in Immunotherapy Management of Esophageal Cancer.
Cancers (Basel). 2025 Mar 1;17(5):851. doi: 10.3390/cancers17050851.
3
Prognostic immune markers in esophageal cancer patients managed with trimodal therapy.
Cancer Immunol Immunother. 2025 Jan 3;74(2):57. doi: 10.1007/s00262-024-03891-3.
5
Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials.
Front Immunol. 2024 Nov 26;15:1501613. doi: 10.3389/fimmu.2024.1501613. eCollection 2024.
6
Targeting esophageal carcinoma: molecular mechanisms and clinical studies.
MedComm (2020). 2024 Oct 15;5(11):e782. doi: 10.1002/mco2.782. eCollection 2024 Nov.
7
Prognostic biomarkers for immunotherapy in esophageal cancer.
Front Immunol. 2024 Sep 30;15:1420399. doi: 10.3389/fimmu.2024.1420399. eCollection 2024.
8
Immune-Related Long Non-Coding RNA Signature Determines Prognosis and Immunotherapeutic Coherence in Esophageal Cancer.
Cancer Inform. 2024 Sep 12;23:11769351241276757. doi: 10.1177/11769351241276757. eCollection 2024.
9
Integrated Germline and Somatic Features Reveal Divergent Immune Pathways Driving Response to Immune Checkpoint Blockade.
Cancer Immunol Res. 2024 Dec 3;12(12):1780-1795. doi: 10.1158/2326-6066.CIR-24-0164.
10
Integrated germline and somatic features reveal divergent immune pathways driving ICB response.
bioRxiv. 2024 Jan 15:2024.01.12.575430. doi: 10.1101/2024.01.12.575430.

本文引用的文献

1
Prognostic Value of Lymphocyte Activation Gene-3 (LAG-3) Expression in Esophageal Squamous Cell Carcinoma.
J Cancer. 2018 Oct 20;9(22):4287-4293. doi: 10.7150/jca.26949. eCollection 2018.
3
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.
Int J Cancer. 2019 Apr 15;144(8):1941-1953. doi: 10.1002/ijc.31937. Epub 2018 Dec 6.
5
[Clinical relevance of common inhibitory immune checkpoint genes in esophageal squamous cell carcinoma].
Zhonghua Yi Xue Za Zhi. 2018 Jun 5;98(21):1703-1706. doi: 10.3760/cma.j.issn.0376-2491.2018.21.016.
7
Second- and third-generation drugs for immuno-oncology treatment-The more the better?
Eur J Cancer. 2017 Mar;74:55-72. doi: 10.1016/j.ejca.2017.01.001. Epub 2017 Feb 10.
8
LAG3 (CD223) as a cancer immunotherapy target.
Immunol Rev. 2017 Mar;276(1):80-96. doi: 10.1111/imr.12519.
9
LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
J Thorac Oncol. 2017 May;12(5):814-823. doi: 10.1016/j.jtho.2017.01.019. Epub 2017 Jan 26.
10
LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma.
Oncoimmunology. 2016 Oct 7;5(11):e1239005. doi: 10.1080/2162402X.2016.1239005. eCollection 2016.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验